Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-668 IR · 1 trial · 1 indication
Cmax of ABBV-668
Tmax of ABBV-668
Terminal phase elimination rate constant (beta) of ABBV-668
Terminal phase elimination half-life of ABBV-668
AUCt of ABBV-668
AUCinf of ABBV-688
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study
| Arm | Type | Description |
|---|---|---|
| ABBV-668 Regimen A | EXPERIMENTAL | Participants will receive ABBV-668 Immediate Release (IR) capsules on Day 1 under fasting conditions |
| ABBV-668 Regimen B | EXPERIMENTAL | Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 1 administered on day 1 under fasting conditions |
| ABBV-668 Regimen C | EXPERIMENTAL | Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 1 administered on day 1 under fed conditions |
| ABBV-668 Regimen D | EXPERIMENTAL | Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 2 administered on day 1 under fasting conditions |
| ABBV-668 Regimen E | EXPERIMENTAL | Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 2 administered on day 1 under fed conditions |
| ABBV-668 Regimen F | EXPERIMENTAL | Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 3 administered on day 1 under fasting conditions |
| ABBV-668 Regimen G | EXPERIMENTAL | Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 3 administered on day 1 under fed conditions |
| Name | Type | Description |
|---|---|---|
| ABBV-668 IR | DRUG | • Oral Capsule |
| ABBV-668 ER | DRUG | • Oral Tablets |
Inclusion Criteria: * BMI is ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at screening. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG. Exclusion Criteria: * History of any...
ABBV-668 IR is an investigational small molecule developed by AbbVie Inc. (ticker ABBV). The IR designation refers to an immediate-release formulation. It is in Phase 1 clinical development, and the specific disease indication has not been disclosed. It is not an approved medicine.
ABBV-668 IR is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the clinical program evaluating this investigational small molecule.
ABBV-668 IR is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
ABBV-668 IR has been studied in one completed Phase 1 trial, NCT06477926, titled A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants. The trial enrolled 25 healthy adult volunteers in the United States and was randomized and controlled.
The completed Phase 1 trial NCT06477926 evaluated the relative bioavailability and food effect of ABBV-668 extended-release formulations in healthy adult participants. It enrolled 25 participants aged 18 years and older in the United States. The study was randomized and controlled but not double-blind.